The increasing complexity of cancer chemotherapy heightens the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy. It will also serve as a review of various agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
von MinckwitzG., CostaS.D., EiermannW.. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol.1999; 17: 1999–2005.
2.
NabholtzJ.M., FalksonC., CamposD.. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol.2003; 21: 968–975.
3.
GanemG., Tubiana-HulinM., FumoleauP.. Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer. Ann Oncol.2003; 14: 1623–1628.
4.
DankM., ZergenyiE., DomotoriZ.S., LahmE., KulkaJ.Primary systemic therapy (PST) of locally advanced breast cancer using doxorubicin/docetaxel combination. Anticancer Res.2003; 23: 2879–2880.
5.
MalhotraV., DorrV.J., LyssA.P.. Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer. Clin Breast Cancer.2004; 5: 377–384.
6.
AlbaE., MartinM., RamosM.. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol.2004; 22: 2587–2593.
7.
MattioliR., LippeP., MassacesiC.. Long-survival in responding patients with metastatic breast cancer treated with doxorubicin-docetaxel combination. A multicentre phase II trial. Anticancer Res.2004; 24: 3257–3261.
8.
EvansT.R., YellowleesA., FosterE.. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol.2005; 23: 2988–2995.
9.
BrainE.G., BachelotT., SerinD.. Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. JAMA.2005; 293: 2367–2371.
10.
BontenbalM., CreemersG.J., BraunH.J.. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol.2005; 23: 7081–708.
11.
DierasV.Docetaxel in combination with doxorubicin: a phase I dose-finding study. Oncology.1997; 11(6 suppl 6): 17–20.
12.
MissetJ.L., DierasV., GruiaG.. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol.1999; 10: 553–560.
13.
ItoY., AibaK., HorikoshiN.. Dose-finding phase I study of simultaneous weekly infusion with doxorubicin and docetaxel in patients with advanced breast cancer. Int J Clin Oncol.2001; 6: 242–247.
14.
MonteroA., BooserD., Esparza-GuerraL.. Phase I trial of dose-dense docetaxel and doxorubicin with or without sargramostim in patients with metastatic breast cancer. Drugs R D.2005; 6: 299–305.
15.
MuthalibA., DarwisI., PrayogoN., Sutjipto. Preliminary results of multicenter phase II trial of docetaxel (Taxotere) in combination with doxorubicin as first line chemotherapy in Indonesian patients with advanced or metastatic breast cancer. Jpn J Cancer Chemother.2000; 27(Suppl 2): 498–504.
16.
TakahashiT., Akashi-TanakaS., FukutomiT.. Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin. Breast Cancer.2001; 8: 234–247.
17.
AiharaT., TakatsukaY., ItohK.. Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer. Oncology.2003; 64: 124–130.
18.
SparanoJ.A., O'NeillA., SchaeferP.L., FalksonC.I., WoodW.C.Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. J Clin Oncol.2000; 18: 2369–2377.
19.
SmithR.E., AndersonS.J., LemberskyB.C., BrownA., MamounasE.Phase II trial of a doxorubicin/docetaxel doublet for locally advanced and metastatic breast cancer: results from national surgical adjuvant breast and bowel project trial BP-57. Clin Breast Cancer.2004; 5: 208–215.
20.
von MinckwitzG., CostaS.D., RaabG.. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J Clin Oncol.2001; 19: 3506–3515.
21.
JackischC., von MinckwitzG., EidtmannH.. Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis. Clin Breast Cancer.2002; 3: 276–280.
22.
MillerK.D., McCaskill-StevensW., SiskJ.. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol.1999; 17: 3033–3037.
23.
PalmeriS., LeonardiV., Tamburo De BellaM.. Doxorubicin-docetaxel sequential schedule: results of front-line treatment in advanced breast cancer. Oncology.2002; 63: 205–212.
24.
MillerK.D., SouleS.E., CalleyC.. Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Res Treat.2005; 89: 187–197.
25.
National Comprehensive Cancer Network. Clinical practice guidelines in oncology – Breast Cancer. V.2.2006. Available at: http://www.nccn.org/. Accessed June 20, 2006.
SavareseD., TaplinM.E., HalabiS., HarsV., KreisW., VogelzangN.A phase II study of docetaxel (Taxotere), estra-mustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of Cancer and Leukemia Group B trial 9780. Semin Oncol.1999; 26(5 suppl 17): 39–44.
28.
HeskethP.J., KrisM.G., GrunbergS.M.. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15: 103–109.
29.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines - Antiemesis. V.2.2006. Available at: http://www.nccn.org/. Accessed June 20, 2006.
30.
KrisM.G., HeskethP.J., SomerfieldM.R.. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol.2006; 24: 2932–2947.
31.
Multinational Association for Supportive Care in Cancer. Antiemetic Guidelines. 2005. Available at: http://www.mascc.org/. Accessed June 20, 2006.
32.
GelingO., EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23: 1289–1294.
33.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
34.
CarmichaelJ., KeizerH.J., CupissolD., MilliezJ., ScheidelP., SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9: 381–385.
35.
de WitR., de BoerA.C., vd LindenG.H., StoterG., SparreboomA., VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 19: 85: 1099–1101.
36.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119: 350–354.
37.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2: 177–183.
38.
ZanottiK.M., MarkhamM.Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf.2001; 24: 767–779.
SmithT.J., KhatcheressianJ., LymanG.H.. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. J Clin Oncol. Epub May 8, 2006. Available at: http://www.jco.org. Accessed June 20, 2006.
42.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology - Myeloid Growth Factors. V.1.2006. Available at: http://www.nccn.org/. Accessed June 20, 2006.
43.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49: 1796–1799.
44.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75: 397–405.
45.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35: 57–74.
